Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. (3rd January 2018)

• Record Type: Journal Article
• Authors: Klein, Klara; Asaad, Shonda; Econs, Michael; Rubin, Janet E
• Is Part Of: BMJ case reports. Volume 2018
• Publication Date: 2018-01-03
• Subjects: contraindications and precautions -- haematology (drugs and medicines) -- gastrointestinal system -- calcium and bone; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2017-222851
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however, a severe, long-lasting hypophosphataemia can lead to osteomalacia with associated bone pain. Lack of awareness of this complication results in delayed time to diagnosis and significant morbidity. We report a case of a patient with Crohn's disease and chronic iron-deficiency anaemia receiving multiple doses of FCM who developed severe hypophosphataemic osteomalacia with urinary phosphate loss and increased FGF23. FGF23 excess and osteomalacia resolved only months after FCM discontinuation and aggressive phosphate repletion. Potential mechanisms of FGF23 dysregulation are discussed, with the aim of raising awareness of this significant side effect for prescribers of chronic intravenous iron supplementation, and to help guide future studies to determine the safety of FCM in all patient populations.